-
Purposeinducible expression of SARS 3CLpro protease
-
Depositing Lab
-
Sequence Information
Ordering
| Item | Catalog # | Description | Quantity | Price (USD) | |
|---|---|---|---|---|---|
| Plasmid | 61692 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 * | |
* Login to view industry pricing.
This item is currently unavailable outside the US without additional regulatory approval.
A non-refundable shipping export licensing fee of $85 is required to cover Addgene’s additional processing costs.
Backbone
-
Vector backbonepGEX-6P-1
-
Backbone manufacturerAmersham
- Backbone size w/o insert (bp) 4984
-
Vector typeBacterial Expression
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameSARS 3CLpro protease
-
SpeciesSARS
- Promoter tac
-
Tags
/ Fusion Proteins
- GST (N terminal on backbone)
- HIS (C terminal on insert)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site BamHI (not destroyed)
- 3′ cloning site EcoRI (not destroyed)
- 5′ sequencing primer pGEX5'
- 3′ sequencing primer pGEX3' (Common Sequencing Primers)
Resource Information
-
Article Citing this Plasmid
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
For protein expression, grow in Rosetta cells.
25 degree induction for 14-15 hours with 0.5 mM IPTG
How to cite this plasmid
( Back to top)
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pGEX-6P-1 SARS-CoV 3CLpro was a gift from Michael Johnson (Addgene plasmid # 61692 ; http://n2t.net/addgene:61692 ; RRID:Addgene_61692) -
For your References section:
Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings. Lee H, Mittal A, Patel K, Gatuz JL, Truong L, Torres J, Mulhearn DC, Johnson ME. Bioorg Med Chem. 2014 Jan 1;22(1):167-77. doi: 10.1016/j.bmc.2013.11.041. Epub 2013 Dec 1. 10.1016/j.bmc.2013.11.041 PubMed 24332657
